Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Primary Objectives: Phase 1: To establish the safety of asciminib in combination with FLAG-Ida and venetoclax. Phase 2: To evaluate the efficacy and toxicity of asciminib in combination with FLAG-Ida and venetoclax. Primary Endpoints: Phase 1: Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatment. Phase 2: Rate of complete response and rate of adverse events. Secondary Objectives: To assess the rates of conversion to CML-CP with this combination. To assess the cytogenetic and molecular response rates with this combination. To assess the survival outcomes with this combination. Secondary Endpoints: Rate of conversion to CML-CP defined as CR/CRi/CRh. Rates of CCyR, MMR, MR4, and MR4.5. Relapse-free survival (RFS) and overall survival.